Atorvia is a pre-clinical stage biotechnology company on a mission to end organ failure, starting in kidney. Leveraging Ai tools and biomarker research, the company translates biological insight into proprietary, transformative medicines to restore organ health and improve patient outcomes for currently untreatable diseases.